Dahan Michel 4
4 · Akebia Therapeutics, Inc. · Filed Feb 29, 2024
Insider Transaction Report
Form 4
Dahan Michel
SVP, Chief Business Officer
Transactions
- Sale
Common Stock
2024-02-27$1.52/sh−10,744$16,331→ 715,593 total
Footnotes (1)
- [F1]This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-third of the reporting person's restricted stock units granted on February 26, 2021.